vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Local Bounti Corporation (LOCL). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $12.5M, roughly 1.6× Local Bounti Corporation). Local Bounti Corporation runs the higher net margin — -69.8% vs -177.4%, a 107.6% gap on every dollar of revenue. On growth, Local Bounti Corporation posted the faster year-over-year revenue change (23.7% vs -11.5%). Local Bounti Corporation produced more free cash flow last quarter ($-3.6M vs $-23.1M). Over the past eight quarters, Local Bounti Corporation's revenue compounded faster (21.9% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.

LAB vs LOCL — Head-to-Head

Bigger by revenue
LAB
LAB
1.6× larger
LAB
$19.6M
$12.5M
LOCL
Growing faster (revenue YoY)
LOCL
LOCL
+35.2% gap
LOCL
23.7%
-11.5%
LAB
Higher net margin
LOCL
LOCL
107.6% more per $
LOCL
-69.8%
-177.4%
LAB
More free cash flow
LOCL
LOCL
$19.5M more FCF
LOCL
$-3.6M
$-23.1M
LAB
Faster 2-yr revenue CAGR
LOCL
LOCL
Annualised
LOCL
21.9%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
LOCL
LOCL
Revenue
$19.6M
$12.5M
Net Profit
$-34.7M
$-8.7M
Gross Margin
48.5%
12.2%
Operating Margin
-168.5%
-106.1%
Net Margin
-177.4%
-69.8%
Revenue YoY
-11.5%
23.7%
Net Profit YoY
-28.8%
76.0%
EPS (diluted)
$-0.09
$1.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
LOCL
LOCL
Q4 25
$12.5M
Q3 25
$19.6M
$12.2M
Q2 25
$21.8M
$12.1M
Q1 25
$40.8M
$11.6M
Q4 24
$10.1M
Q3 24
$22.1M
$10.2M
Q2 24
$22.5M
$9.4M
Q1 24
$45.5M
$8.4M
Net Profit
LAB
LAB
LOCL
LOCL
Q4 25
$-8.7M
Q3 25
$-34.7M
$-26.4M
Q2 25
$-33.5M
$-21.6M
Q1 25
$-26.0M
$-37.7M
Q4 24
$-36.3M
Q3 24
$-26.9M
$-34.3M
Q2 24
$-45.7M
$-25.3M
Q1 24
$-32.2M
$-24.1M
Gross Margin
LAB
LAB
LOCL
LOCL
Q4 25
12.2%
Q3 25
48.5%
11.5%
Q2 25
48.8%
12.2%
Q1 25
48.4%
12.6%
Q4 24
5.4%
Q3 24
54.9%
13.8%
Q2 24
46.1%
14.3%
Q1 24
53.1%
9.4%
Operating Margin
LAB
LAB
LOCL
LOCL
Q4 25
-106.1%
Q3 25
-168.5%
-149.4%
Q2 25
-118.1%
-127.7%
Q1 25
-80.8%
-135.6%
Q4 24
-166.6%
Q3 24
-120.9%
-176.0%
Q2 24
-134.5%
-146.8%
Q1 24
-132.2%
-122.9%
Net Margin
LAB
LAB
LOCL
LOCL
Q4 25
-69.8%
Q3 25
-177.4%
-216.6%
Q2 25
-153.7%
-178.3%
Q1 25
-63.8%
-324.6%
Q4 24
-360.1%
Q3 24
-122.0%
-335.2%
Q2 24
-203.3%
-267.6%
Q1 24
-70.6%
-286.9%
EPS (diluted)
LAB
LAB
LOCL
LOCL
Q4 25
$1.52
Q3 25
$-0.09
$-1.18
Q2 25
$-0.09
$-1.63
Q1 25
$-0.07
$-4.32
Q4 24
$-4.24
Q3 24
$-0.07
$-4.01
Q2 24
$-0.12
$-3.00
Q1 24
$-0.27
$-2.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
LOCL
LOCL
Cash + ST InvestmentsLiquidity on hand
$129.4M
$4.2M
Total DebtLower is stronger
$483.1M
Stockholders' EquityBook value
$399.7M
$-166.2M
Total Assets
$539.6M
$410.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
LOCL
LOCL
Q4 25
$4.2M
Q3 25
$129.4M
$6.2M
Q2 25
$158.6M
$5.3M
Q1 25
$150.9M
$18.0M
Q4 24
$937.0K
Q3 24
$210.6M
$317.0K
Q2 24
$269.8M
$9.7M
Q1 24
$287.1M
$8.2M
Total Debt
LAB
LAB
LOCL
LOCL
Q4 25
$483.1M
Q3 25
$484.9M
Q2 25
$478.3M
Q1 25
$480.0M
Q4 24
$436.8M
Q3 24
$55.2M
$398.4M
Q2 24
$55.1M
$374.0M
Q1 24
$55.0M
$329.8M
Stockholders' Equity
LAB
LAB
LOCL
LOCL
Q4 25
$-166.2M
Q3 25
$399.7M
$-158.1M
Q2 25
$424.5M
$-132.7M
Q1 25
$454.6M
$-134.5M
Q4 24
$-100.5M
Q3 24
$489.3M
$-65.6M
Q2 24
$510.3M
$-32.8M
Q1 24
$577.3M
$-9.4M
Total Assets
LAB
LAB
LOCL
LOCL
Q4 25
$410.5M
Q3 25
$539.6M
$417.8M
Q2 25
$557.0M
$426.8M
Q1 25
$579.6M
$447.2M
Q4 24
$428.0M
Q3 24
$681.5M
$430.8M
Q2 24
$708.7M
$438.1M
Q1 24
$777.7M
$413.4M
Debt / Equity
LAB
LAB
LOCL
LOCL
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
LOCL
LOCL
Operating Cash FlowLast quarter
$-22.2M
$-3.1M
Free Cash FlowOCF − Capex
$-23.1M
$-3.6M
FCF MarginFCF / Revenue
-118.1%
-29.1%
Capex IntensityCapex / Revenue
4.5%
3.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$-42.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
LOCL
LOCL
Q4 25
$-3.1M
Q3 25
$-22.2M
$-8.9M
Q2 25
$-20.7M
$-8.7M
Q1 25
$-30.3M
$-9.6M
Q4 24
$1.2M
Q3 24
$-27.9M
$-17.2M
Q2 24
$-39.0M
$-4.0M
Q1 24
$-62.5M
$-7.1M
Free Cash Flow
LAB
LAB
LOCL
LOCL
Q4 25
$-3.6M
Q3 25
$-23.1M
$-10.1M
Q2 25
$-22.6M
$-14.6M
Q1 25
$-35.3M
$-14.5M
Q4 24
$-8.6M
Q3 24
$-30.1M
$-30.0M
Q2 24
$-41.0M
$-28.8M
Q1 24
$-63.3M
$-42.1M
FCF Margin
LAB
LAB
LOCL
LOCL
Q4 25
-29.1%
Q3 25
-118.1%
-82.8%
Q2 25
-103.6%
-121.0%
Q1 25
-86.6%
-125.1%
Q4 24
-85.3%
Q3 24
-136.4%
-293.1%
Q2 24
-182.2%
-305.4%
Q1 24
-138.9%
-501.8%
Capex Intensity
LAB
LAB
LOCL
LOCL
Q4 25
3.9%
Q3 25
4.5%
9.7%
Q2 25
8.7%
48.9%
Q1 25
12.4%
42.8%
Q4 24
97.6%
Q3 24
10.2%
125.0%
Q2 24
8.6%
263.0%
Q1 24
1.7%
417.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

LOCL
LOCL

Segment breakdown not available.

Related Comparisons